Read by QxMD icon Read

Follicular lymphoma elderly

C Demoor-Goldschmidt, P Agape, I Barillot, M A Mahé
Treatment with monoclonal antibodies, especially rituximab, is more and more frequent and questions the interest of radiotherapy in limited stages of diffuse B-cell large cell and follicular non-Hodgkin's lymphomas. From a review of literature, it appears that radiotherapy is of interest in bulky disease, patients with incomplete metabolic response, elderly patients receiving short chemotherapy and those with recurrence after exclusive chemotherapy. Finally, this article gives recommendations on available techniques of radiotherapy and doses to be delivered...
October 2016: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
Frank Verhoeven, Xavier Guillot, Mickaël Chouk, Clément Prati, Daniel Wendling
Introduction. Polymyalgia rheumatica (PMR) is one of the most common inflammatory rheumatism types in elderly population. The link between cancer and PMR is a matter of debate. Methods. We report two cases of PMR leading to the diagnosis of lymphoma and the growing interest of PET-TDM in this indication. Results. A 84-year-old man known for idiopathic neutropenia presented an inflammatory arthromyalgia of the limb girdle since one month. Blood exams highlighted the presence of a monoclonal B cell clone. Bone marrow concluded to a B cell lymphoma of the marginal zone...
2016: Case Reports in Rheumatology
Roberto Castelli, Antonio Gidaro, Giorgio Lambertenghi Deliliers
BACKGROUND: Splenic marginal zone lymphoma (SMZL) is a chronic B-cell lymphoproliferative disorder, comprising less than 2% of non-Hodgkin's lymphomas, and affecting mainly middle-aged and elderly patients with a median survival of >10 years. The typical clinical features of SMZL include splenomegaly. Treatment should be patient-tailored and can range from a 'watchful waiting' approach for asymptomatic patients without cytopenias to surgery, localized radiation therapy or immuno/chemotherapies...
2016: Mediterranean Journal of Hematology and Infectious Diseases
Alice Johl, Eva Lengfelder, Wolfgang Hiddemann, Wolfram Klapper
Current guidelines of the European Society of Medical Oncology recommend surgical excision biopsies of lymph nodes for the diagnosis of lymphoma whenever possible. However, core needle biopsies are increasingly used. We aimed to understand the common practice to choose the method of biopsy in Germany. Furthermore, we wanted to understand performance of surgical excision and core needle biopsies of lymph nodes in the diagnosis of lymphoma. The files of 1510 unselected, consecutive lymph node specimens from a consultation center for lymphoma diagnosis were analyzed...
August 2016: Annals of Hematology
Patrizia Mondello, Salvatore Cuzzocrea, Michele Navarra, Michael Mian
Y-ibritumomab tiuxetan (90Y-IT) combines the benefits of a monoclonal antibody with the efficacy of radiation in the treatment of B-cell non-Hodgkin lymphoma (NHL), a remarkably radiosensitive hematologic malignancy. 90Y-IT activity has been well established in the indolent setting, being approved in front-line treatment of follicular lymphoma (FL) patients as well as salvage therapy. However, no advantage in OS was observed with respect to standard treatment. Promising data are available also for aggressive B-cell lymphoma...
February 16, 2016: Oncotarget
Futoshi Iioka, Kiyotaka Izumi, Yoshimasa Kamoda, Takashi Akasaka, Hitoshi Ohno
BACKGROUND: Although the number of patients aged 80 years or older with aggressive B-cell non-Hodgkin lymphoma (B-NHL) has increased in the clinical setting, management has been challenging due to lower tolerability. The aim of the present study was to evaluate the efficacy and safety of reduced-dose chemotherapy for very elderly patients. METHODS: We retrospectively analyzed the clinical outcomes of patients aged ≥80 years old with diffuse large B-cell lymphoma (n = 58) or grade 3 follicular lymphoma (n = 3)...
June 2016: International Journal of Clinical Oncology
Manasi Agrawal, Olga C Aroniadis, Lawrence J Brandt, Colleen Kelly, Sarah Freeman, Christina Surawicz, Elizabeth Broussard, Neil Stollman, Andrea Giovanelli, Becky Smith, Eugene Yen, Apurva Trivedi, Levi Hubble, Dina Kao, Thomas Borody, Sarah Finlayson, Arnab Ray, Robert Smith
OBJECTIVES: Clostridium difficile infection (CDI) in the elderly has a higher prevalence, greater morbidity and mortality, and lower response to conventional treatment than the general population. Fecal microbiota transplant (FMT) is highly effective therapy for CDI but has not been studied specifically in the elderly. This study aims to determine the long-term efficacy and safety of FMT for recurrent (RCDI), severe (SCDI), and complicated (CCDI) CDI in elderly patients. METHODS: A multicenter, long-term follow-up study was performed with demographic, pre-FMT, and post-FMT data collected from elderly patients with RCDI, SCDI, and CCDI, through a 47-item questionnaire...
May 2016: Journal of Clinical Gastroenterology
E Hermet, A Cabrespine, R Guièze, A Garnier, A Tempescul, P Lenain, R Bouabdallah, J P Vilque, J Frayfer, D Bordessoule, D Sibon, M Janvier, D Caillot, P Biron, L Legros, B Choufi, B Drenou, N C Gorin, K Bilger, J Tamburini, C Soussain, S Brechignac, J O Bay
INTRODUCTION: Limited data is available on the feasibility of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) in elderly patients over 70 years of age with non-Hodgkin's lymphoma (NHL). MATERIALS AND METHODS: In the setting of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) group, we retrospectively analyzed 81 consecutive patients with NHL over 70 years of age who received AHSCT. RESULTS: The median age at AHSCT was 72...
September 2015: Journal of Geriatric Oncology
Chadi Nabhan, Michelle Byrtek, Ashish Rai, Keith Dawson, Xiaolei Zhou, Brian K Link, Jonathan W Friedberg, Andrew D Zelenetz, Matthew J Maurer, James R Cerhan, Christopher R Flowers
Data from the National LymphoCare Study (a prospective, multicentre registry that enrolled follicular lymphoma (FL) patients from 2004 to 2007) were used to determine disease characteristics, treatment patterns, outcomes and prognosis for elderly FL (eFL) patients. Of 2650 FL patients, 209 (8%) were aged >80 years; these eFL patients more commonly had grade 3 disease, less frequently received chemoimmunotherapy and anthracyclines, and had lower response rates when compared to younger patients. With a median follow-up of 6...
July 2015: British Journal of Haematology
Bing Bai, Hui-Qiang Huang
Follicular lymphoma (FL) is the most common indolent non-hodgkin lymphoma. Most patients with FL are diagnosed with advanced disease and are considered incurable. The classical prognostic index in FL is the FL international prognostic index (FLIPI). The management of FL is mainly determined by histologic grading, clinical stage, and tumor burden. For patients with stage I and II disease, an involved-site radiation therapy (ISRT) is recommended and may be potentially curative approach with 60% to 80% of 10-year overall survival (OS) rates, while patients with stage III and IV should be treated with systemic therapy...
March 2015: Chinese Clinical Oncology
Qingshan Yang, Prexy Modi, Terry Newcomb, Christophe Quéva, Varsha Gandhi
Idelalisib [Zydelig (Gilead Sciences, Inc.), also known as CAL-101 and GS-1101] was approved in 2014 in the United States and European Union for the treatment of three indolent B-cell neoplasms: relapsed/refractory chronic lymphocytic leukemia (CLL, in combination with rituximab), relapsed follicular lymphoma, and relapsed small lymphocytic lymphoma (as monotherapy). Furthermore, it was approved in the European Union as first-line therapy for poor-prognosis CLL with 17p deletions or TP53 mutations and in patients unsuitable for chemoimmunotherapy...
April 1, 2015: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Peir-In Liang, Sheng-Tsung Chang, Ming-Yen Lin, Yen-Chuan Hsieh, Pei-Yi Chu, Chih-Jung Chen, Kai-Jen Lin, Yun-Chih Jung, Wei-Shou Hwang, Wen-Tsung Huang, Wei-Chin Chang, Hongtao Ye, Shih-Sung Chuang
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive peripheral T-cell lymphoma (PTCL) of follicular helper T-cell origin and is rare in Taiwan. There are overlapping features of AITL and peripheral T-cell lymphoma with a follicular growth pattern (PTCL-F). Around one fifth of PTCL-F exhibits t(5;9)(q33;q22)/ITK-SYK chromosomal translocation, which is essentially absent in AITL. We retrospectively investigated 35 cases of AITL from Taiwan with histopathology review, immunohistochemistry, in situ hybridization for Epstein-Barr virus (EBV) and fluorescence in situ hybridization (FISH) for t(5;9)(q33;q22)/ITK-SYK and correlated the results with overall survival...
2014: International Journal of Clinical and Experimental Pathology
Misato Kikuchi, Hideki Nakasone, Yu Akahoshi, Hirofumi Nakano, Tomotaka Ugai, Hidenori Wada, Ryoko Yamasaki, Kana Sakamoto, Koji Kawamura, Yuko Ishihara, Miki Sato, Masahiro Ashizawa, Kiriko Terasako-Saito, Shun-ichi Kimura, Rie Yamazaki, Shinichi Kako, Junya Kanda, Junji Nishida, Naohiro Sekiguchi, Satoshi Noto, Michiko Kida, Akira Hangaishi, Kensuke Usuki, Yoshinobu Kanda
Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated the efficacy and toxicity of reduced-dose (two-thirds) R-CHOP chemotherapy as an initial chemotherapy for 45 patients aged 70 years or older with B-cell NHL. The WHO classification of NHL included diffuse large B-cell lymphoma (DLBCL) (31), mantle cell lymphoma (5), follicular lymphoma (4), extranodal marginal zone lymphoma (1), Burkitt lymphoma (1), and B-cell lymphoma whose further types were unclassified (3)...
February 2015: Journal of Chemotherapy
H R Junlén, S Peterson, E Kimby, S Lockmer, O Lindén, H Nilsson-Ehle, M Erlanson, H Hagberg, A Rådlund, O Hagberg, B E Wahlin
Treatment for follicular lymphoma (FL) improved with rituximab. In Sweden, first-line rituximab was gradually introduced between 2003 and 2007, with regional differences. The first national guidelines for FL were published in November 2007, recommending rituximab in first-line therapy. Using the population-based Swedish Lymphoma Registry, 2641 patients diagnosed with FL from 2000 to 2010 were identified and characterized by year and region of diagnosis, age (median, 65 years), gender (50% men), first-line therapy and clinical risk factors...
March 2015: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Peter K Rasmussen, Elisabeth Ralfkiaer, Jan U Prause, Lene D Sjö, Lena Specht, Henrik H Rossing, Volkert D Siersma, Steffen Heegaard
PURPOSE: To characterize the clinicopathological features of follicular lymphoma of the ocular adnexal region. METHODS: Retrospective nation-based study of Danish patients with ocular adnexal follicular lymphoma from January 1st 1980 through December 31st 2009. RESULTS: Twenty-four patients with ocular adnexal follicular lymphoma were identified. Fourteen (58%) of the patients were females. The median age was 63 years (range: 42-96 years)...
March 2015: Acta Ophthalmologica
Milena Sant, Pamela Minicozzi, Morgane Mounier, Lesley A Anderson, Hermann Brenner, Bernd Holleczek, Rafael Marcos-Gragera, Marc Maynadié, Alain Monnereau, Gemma Osca-Gelis, Otto Visser, Roberta De Angelis
BACKGROUND: More effective treatments have become available for haematological malignancies from the early 2000s, but few large-scale population-based studies have investigated their effect on survival. Using EUROCARE data, and HAEMACARE morphological groupings, we aimed to estimate time trends in population-based survival for 11 lymphoid and myeloid malignancies in 20 European countries, by region and age. METHODS: In this retrospective observational study, we included patients (aged 15 years and older) diagnosed with haematological malignancies, diagnosed up to Dec 31, 2007, and followed up to Dec 31, 2008...
August 2014: Lancet Oncology
Antonio C Sánchez Ruiz, Luis de la Cruz-Merino, Mariano Provencio Pulla
Non-Hodgkin's lymphoma (NHL) accounts for 4% of all cancers diagnosed in the United States. Follicular lymphoma (FL) is the most common type of indolent NHL with a survival from 5 to 15 years. Although it is very sensitive to chemotherapy and radiotherapy, relapses are the main cause of therapeutic failure, and currently there is no consensus on the first-line treatment and optimal therapeutic strategies for patients with FL. Immediate treatment offers any survival benefit for asymptomatic and more indolent disease...
June 2014: Therapeutic Advances in Hematology
Umberto Vitolo, Annalisa Chiappella, Silvia Franceschetti, Angelo Michele Carella, Ileana Baldi, Giorgio Inghirami, Michele Spina, Vincenzo Pavone, Marco Ladetto, Anna Marina Liberati, Anna Lia Molinari, Pierluigi Zinzani, Flavia Salvi, Pier Paolo Fattori, Alfonso Zaccaria, Martin Dreyling, Barbara Botto, Alessia Castellino, Angela Congiu, Marcello Gaudiano, Manuela Zanni, Giovannino Ciccone, Gianluca Gaidano, Giuseppe Rossi
BACKGROUND: Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma (DLBCL) given a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) relapse or develop refractory disease. Lenalidomide has high activity in relapsed or refractory aggressive B-cell lymphomas. In phase 2 of the REAL07 trial, we aimed to establish the safety and efficacy of the combination of lenalidomide and R-CHOP21 in elderly patients with untreated DLBCL...
June 2014: Lancet Oncology
Peter K Rasmussen, Sarah E Coupland, Paul T Finger, Gerardo F Graue, Hans E Grossniklaus, Santosh G Honavar, Penny McKelvie, Kaustubh Mulay, Jan U Prause, Elisabeth Ralfkiaer, Lene D Sjö, Steffen Heegaard
IMPORTANCE: The clinical features of the follicular subtype of ocular adnexal lymphoma (OAL) have not been previously evaluated in a large cohort. OBJECTIVE: To characterize the clinical features of follicular OAL. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective multicenter study that involved 6 eye cancer centers from January 1, 1980, through December 31, 2010. A total of 105 patients with follicular OAL were identified, of which 7 patients were excluded because of missing clinical data...
July 2014: JAMA Ophthalmology
Anna Schmitt, Pierre Soubeyran
Follicular lymphoma is essentially a disease of the elderly, and the aging of the population in developed countries will increase patient numbers in coming years. Significant achievements have been made for treatment, but better understanding of the disease and major progress in biology now facilitate the development of many new drugs, which may have improved toxicity profiles making them appropriate for treatment of older adults. However, the increasing number of treatment possibilities, can also increase the toxicity risks, and unexpected toxicities specific to older adults may be encountered...
June 2014: Anti-cancer Agents in Medicinal Chemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"